A Boswellia serrata ingredient marketed as Dynagenix Muscle + Joint Formula by PLT Health Solutions can support joint comfort, flexibility, muscle recovery, and functional mobility after just five days of treatment, according to a new study.

The randomized, double-blind, placebo-controlled study evaluated 72 men and women between the ages of 40 and 70 with grade II osteoarthritis, who either received a placebo or 40 mg per day of Dynagenix for 30 days.

By day five, significant improvements were observed in measures of joint comfort, stiffness, and function, PLT reported. Within 15 days, participants experienced enhanced flexibility and improved physical performance, which gradually improved until day 30 across a range of mobility tests.

“This second clinical study validates Dynagenix as a true category-advancing ingredient,” said Seth Flowerman, CEO of PLT Health Solutions. “It offers fast, meaningful results in joint and muscle comfort—whether you’re an athlete returning to activity or someone looking to move through daily life with less discomfort and more ease. And thanks to its low-dose, water-soluble form, it offers exciting innovation potential for formulators.”

Key outcomes in the study included self-reported pain, stiffness, and function in the WOMAC questionnaire, a 30-second chair stand test, a six-minute walking test, a stair climb test, and knee flexion and range of motion assessments. The researchers also tested biomarkers related to inflammation.

According to PLT Health, subjects consuming Dynagenix experienced:

• 47% improvement in joint comfort
• 47% reduction in joint stiffness
• 45% improvement in joint function
• 46% improvement in overall joint health

Meanwhile, functional performance test results indicated:

• 25% increase in Chair Stand Test performance at 2 weeks
• 25% faster stair navigation (4 seconds faster)
• 15.4% increase in walking speed, with subjects walking 47 meters farther in 6 minutes
• 14% improvement in flexibility

This new study builds on a 2019 clinical trial, which assessed delayed onset muscle soreness in recreationally active men. In that study, a 60 mg daily dose of Dynagenix was associated with:

• Reduced muscle soreness by up to 47%
• Reduced joint soreness during exercise by 31%
• Increased strength recovery, with 96% of subjects regaining full strength by Day 3—2.5x higher than placebo
• Lowered perceived exertion by up to 27%
• Improved inflammatory biomarkers related to muscle and connective tissue stress

“Dynagenix now has robust data across two different populations and usage occasions,” said Jennifer Murphy, director of innovation and clinical development at PLT. “From reducing soreness and accelerating recovery post-exercise to improving everyday joint function in older adults, Dynagenix delivers fast, measurable benefits at a very low 40mg effective dose. At PLT, we are enthusiastic about how these results will allow brands to deliver superior joint health support across a wider range of palatable, easy-to-consumer products in consumer-preferred formats like gummies, shots, sachets, and stick-packs, and expand its potential for helping people live happier, healthier lives.”